hyperuricemia
Conditions
Interventions
promoting drug (benclomarone):Treatment with benzbromarone
suppressing synthetic drugs (febustat ):Treatment with febuxostat
suppressing synthetic drugs (allopurinol):Treatment with allopurinol
Sponsors
Shanghai Tenth People's Hospital affiliated to Tongji University
Eligibility
Sex/Gender
Male
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18 to 75 years old, male; 2. did not use uric acid lowering drugs before enrollment; 3. It is expected that the drug will be used for more than one year after enrollment; 4. Have complete baseline data; 5. in line with low purine diet; 6. There was no history of stress events such as infection and trauma in the past two weeks before enrollment.
Exclusion criteria
Exclusion criteria: 1. Have a history of any malignant tumor in the past 5 years; 2. People with active liver disease or abnormal liver function (ALT, AST, TBIL are more than 3 times the upper limit of normal values); or have a history of liver cirrhosis, decompensated stage of liver cirrhosis, or a history of liver encephalopathy; 3. Severe kidney disease; 4. Acute and chronic inflammatory lesions.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Blood biochemical tests; | — |
Secondary
| Measure | Time frame |
|---|---|
| ultrasound;Urine biochemical test; | — |
Countries
China
Contacts
Public ContactHaibing Chen
Shanghai Tenth People's Hospital affiliated to Tongji University
Outcome results
None listed